ATE374028T1 - Kristallines isoxazol-derivat und medizinisches präparat daraus - Google Patents

Kristallines isoxazol-derivat und medizinisches präparat daraus

Info

Publication number
ATE374028T1
ATE374028T1 AT02705512T AT02705512T ATE374028T1 AT E374028 T1 ATE374028 T1 AT E374028T1 AT 02705512 T AT02705512 T AT 02705512T AT 02705512 T AT02705512 T AT 02705512T AT E374028 T1 ATE374028 T1 AT E374028T1
Authority
AT
Austria
Prior art keywords
medical preparation
isoxazole derivative
crystalline
crystalline isoxazole
derivative
Prior art date
Application number
AT02705512T
Other languages
English (en)
Inventor
Yasushi Ochiai
Kazuhiko Tomomura
Hiroyuki Nishii
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Application granted granted Critical
Publication of ATE374028T1 publication Critical patent/ATE374028T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT02705512T 2001-03-27 2002-03-26 Kristallines isoxazol-derivat und medizinisches präparat daraus ATE374028T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001089119 2001-03-27

Publications (1)

Publication Number Publication Date
ATE374028T1 true ATE374028T1 (de) 2007-10-15

Family

ID=18944099

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02705512T ATE374028T1 (de) 2001-03-27 2002-03-26 Kristallines isoxazol-derivat und medizinisches präparat daraus

Country Status (11)

Country Link
US (2) US7429588B2 (de)
EP (1) EP1374871B1 (de)
JP (1) JP4498679B2 (de)
KR (1) KR100897218B1 (de)
CN (1) CN100522174C (de)
AT (1) ATE374028T1 (de)
CA (1) CA2441798C (de)
DE (1) DE60222643T2 (de)
ES (1) ES2292721T3 (de)
TW (2) TWI312683B (de)
WO (1) WO2002092094A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092094A1 (en) * 2001-03-27 2002-11-21 Sumitomo Pharmaceuticals Co., Ltd. Crystalline isoxazole derivative and medical preparation thereof
PT1603553E (pt) * 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
EP1623709A4 (de) * 2003-04-30 2007-09-05 Dainippon Sumitomo Pharma Co Mittel zur behandlung von rheumatoider arthritis
CA2589808A1 (en) * 2004-11-02 2006-05-11 Dainippon Sumitomo Pharma Co., Ltd. Combination drug for treating autoimmune disease
JPWO2007046411A1 (ja) * 2005-10-19 2009-04-23 大日本住友製薬株式会社 イソキサゾール化合物の安定化方法
EP2228175B1 (de) * 2009-03-12 2013-06-19 Ferton Holding SA Verwendung eines Pulvers oder Pulvergemisches zur Herstellung eines Mittels zur Pulverstrahlreinigung von Zahnoberflächen
CN113582913B (zh) * 2021-08-18 2023-01-03 河北广祥制药有限公司 一种连续精制硝苯地平的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100260A (en) 1997-04-21 2000-08-08 Sumitomo Pharmaceutical Company, Limited Isoxazole derivatives
DK0979226T3 (da) * 1997-04-21 2006-03-06 Dainippon Sumitomo Pharma Co Isoxazolderivater
JP3237608B2 (ja) * 1997-04-21 2001-12-10 住友製薬株式会社 イソキサゾール誘導体
JP3244672B2 (ja) * 1998-10-13 2002-01-07 住友製薬株式会社 イソキサゾール誘導体からなる医薬
JP3304321B2 (ja) 1998-10-15 2002-07-22 住友製薬株式会社 ５−アミノイソキサゾール誘導体の製造方法
WO2000028991A1 (en) 1998-11-13 2000-05-25 Fujisawa Pharmaceutical Co., Ltd. Remedies for polycystic ovary syndrome
IL150187A0 (en) * 1999-12-14 2002-12-01 Biogal Pharmaceutical Co Ltd Novel forms of pravastatin sodium
WO2002092094A1 (en) * 2001-03-27 2002-11-21 Sumitomo Pharmaceuticals Co., Ltd. Crystalline isoxazole derivative and medical preparation thereof
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
JP2005529933A (ja) * 2002-05-31 2005-10-06 シェーリング　コーポレイション キサンチンホスホジエステラーゼｖインヒビター多形体
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US7186842B2 (en) * 2003-02-12 2007-03-06 Usv, Ltd. Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof
NZ546011A (en) * 2003-10-21 2009-09-25 Warner Lambert Co Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide

Also Published As

Publication number Publication date
CN1499973A (zh) 2004-05-26
TW200624121A (en) 2006-07-16
CA2441798C (en) 2009-10-20
KR100897218B1 (ko) 2009-05-14
EP1374871A1 (de) 2004-01-02
CN100522174C (zh) 2009-08-05
DE60222643T2 (de) 2008-07-17
EP1374871B1 (de) 2007-09-26
ES2292721T3 (es) 2008-03-16
EP1374871A4 (de) 2005-09-14
US20040082580A1 (en) 2004-04-29
DE60222643D1 (de) 2007-11-08
JPWO2002092094A1 (ja) 2004-08-26
TWI273909B (en) 2007-02-21
KR20030085059A (ko) 2003-11-01
US7429588B2 (en) 2008-09-30
WO2002092094A1 (en) 2002-11-21
TWI312683B (en) 2009-08-01
US20080311212A1 (en) 2008-12-18
CA2441798A1 (en) 2002-11-21
JP4498679B2 (ja) 2010-07-07

Similar Documents

Publication Publication Date Title
CO5271691A1 (es) Nuevos compuestos
SE0200979D0 (sv) New compounds
GB0003154D0 (en) Novel compounds
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
SE9904176D0 (sv) New use
SE0203754D0 (sv) New compounds
SE0102439D0 (sv) New compounds
TW200745111A (en) New compounds
IL114894A (en) Pyrrolidine derivatives as endothelin antagonists, pharmaceutical compositions containing them, and their use in the preparation of medicaments
HUT54357A (en) Process for producing benzilidene-(azolylmethyl)-cycloalkane and -cycloalkene derivatives, fungicidal compositions comprising such compounds as active ingredient and intermediates usable for the production of the active ingredients
HUP0204399A3 (en) Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
DE69822218D1 (de) Donepezil polykristalle und verfharen zu ihrer herstellung
DE60219954D1 (de) Neue Indol-2-on Derivate
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
ATE170510T1 (de) 3-(hydroxybenzylidenyl)-indolin-2-one und diese enthaltende arzneimittel
NO20021448L (no) Nye tiazolo-(4,5-D)pyrimidinforbindelser
MY136269A (en) Novel diphenylazetidinone, process for its preparation, medicaments comprising this compound and their use
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
SG149695A1 (en) Chemical compounds
SE0100569D0 (sv) New compounds
GB0109122D0 (en) Novel compounds
ATE374028T1 (de) Kristallines isoxazol-derivat und medizinisches präparat daraus
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
PT992509E (pt) Novos derivados macrolidos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1374871

Country of ref document: EP